Results 11 to 20 of about 614,006 (307)
Biomarker Research, 2017 Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors.
Cheng Zhang +3 more
doaj +3 more sources
Pharmacologic Control of CAR T Cells [PDF]
International Journal of Molecular Sciences, 2021 Chimeric antigen receptor (CAR) therapy is a promising modality for the treatment of advanced cancers that are otherwise incurable. During the last decade, different centers worldwide have tested the anti-CD19 CAR T cells and shown clinical benefits in the treatment of B cell tumors.
Benjamin Caulier +2 more
openaire +4 more sources
International Journal of Molecular Sciences, 2020 CAR-T therapy has revolutionized the treatment of select hematological malignancies, namely, acute lymphoblastic leukemia and large B-cell lymphomas [...]
openaire +6 more sources
An NK-like CAR T cell transition in CAR T cell dysfunction
Cell, 2021 Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell exhaustion in the solid tumor microenvironment. To study dysfunction of mesothelin-redirected CAR T cells in pancreatic cancer, we establish a robust model of continuous antigen ...
Charly R. Good +29 more
openaire +3 more sources
Journal of Hematology & Oncology, 2019 The current treatment for pediatric acute lymphoblastic leukemia (ALL) is highly successful with high cure rate. However, the treatment of adult ALL remains a challenge, particularly for refractory and/or relapsed (R/R) ALL.
Juanjuan Zhao, Yongping Song, Delong Liu
doaj +1 more source
Frontiers in Immunology, 2023 Chimeric antigen receptor (CAR)-T cell therapy is an innovative treatment for CD19-expressing lymphomas. CAR-T cells are primarily manufactured via lentivirus transfection or transposon electroporation.
Anna Niu +11 more
doaj +1 more source
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. [PDF]
, 2018 Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of
Avanzi, Mauro P +10 more
core +1 more source
CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
Frontiers in Immunology, 2019 Re-directing T cells via chimeric antigen receptors (CARs) was first tested in HIV-infected individuals with limited success, but these pioneering studies laid the groundwork for the clinically successful CD19 CARs that were recently FDA approved.
Gloria B. Kim +2 more
doaj +1 more source
Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings
ImmunoInformatics, 2023 Chimeric antigen receptor (CAR) T-cell based immunotherapy has shown its potential in treating blood cancers, and its application to solid tumors is currently being extensively investigated.
Runpeng Li +6 more
doaj +1 more source
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]
, 2018 Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B. +5 more
core +2 more sources